This program will provide an overview of the status of COVID-19 in Mississippi and the impact health risks & co-morbidities that increase the risk of COVID-19 morbidity and mortality. Some of the key health issues to be discussed include obesity, diabetes, and other metabolic health risks and conditions. Also discussed will be specific characteristics of diabetes which can lead to poor COVID-19 outcomes, especially with those patients with uncontrolled diabetes. Other information will be shared on how obesity is associated with multiple complications such as inflammation, hypertension, and breathing problems, which can all contribute to poor COVID-19 outcomes. Ideas for solutions by employer-sponsored health plans will also be discussed.
Dr. Rachel Thomas is a Medical Accounts Associate Director for Novo Nordisk, covering the Midsouth area (Mississippi, Alabama, Georgia, Tennessee). Dr. Thomas received a B.A. in biochemistry from the University of Mississippi and a Master of Science degree in chemistry from the University of Alabama at Birmingham. She earned a Doctor of Pharmacy degree from the McWhorter School of Pharmacy and completed a postgraduate residency in drug information.